On January 7, Eli Lilly announced that it will acquire Loxo Oncology for $235 per share in full cash, totaling $8 billion.The deal is scheduled to be completed in 2019Q1.
Loxo Oncology has a range of drugs with considerable market potential in its pipeline, including:
LOXO-292, a RET inhibitor of First in Class, which has been granted FDA qualification for breakthrough therapies for three indications and is expected to be approved for the first time in 2020.RET fusions and mutations occur in a variety of tumor types, including lung cancer, thyroid cancer, and some other tumor types (head-to-head competition for new generation star RET inhibitors: BLU-667 vs LOXO-292).
LOXO-305, an oral BTK inhibitor, is currently in Phase I/II.
Vitrakvi, an oral TRK inhibitor of the first-in-class, developed jointly by Loxo and Bayer and just approved by the FDA, is Keytruda's second oncology drug based on tumor molecular markers without distinguishing between tumor types.
LOXO-195, a TRK inhibitor, developed jointly by LOXO and Bayer for patients with acquired resistance to TRK inhibitors, is expected to be approved in 2022.